Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201491796> ?p ?o ?g. }
- W3201491796 endingPage "4620" @default.
- W3201491796 startingPage "4620" @default.
- W3201491796 abstract "Monoclonal antibodies have revolutionized the treatment of many diseases, but their clinical efficacy remains limited in some other cases. Pre-clinical and clinical trials have shown that combinations of antibodies that bind to the same target (homo-combinations) or to different targets (hetero-combinations) to mimic the polyclonal humoral immune response improve their therapeutic effects in cancer. The approval of the trastuzumab/pertuzumab combination for breast cancer and then of the ipilimumab/nivolumab combination for melanoma opened the way to novel antibody combinations or oligoclonal antibody mixtures as more effective biologics for cancer management. We found more than 300 phase II/III clinical trials on antibody combinations, with/without chemotherapy, radiotherapy, small molecules or vaccines, in the ClinicalTrials.gov database. Such combinations enhance the biological responses and bypass the resistance mechanisms observed with antibody monotherapy. Usually, such antibody combinations are administered sequentially as separate formulations. Combined formulations have also been developed in which separately produced antibodies are mixed before administration or are produced simultaneously in a single cell line or a single batch of different cell lines as a polyclonal master cell bank. The regulation, toxicity and injection sequence of these oligoclonal antibody mixtures still need to be addressed in order to optimize their delivery and their therapeutic effects." @default.
- W3201491796 created "2021-09-27" @default.
- W3201491796 creator A5038051309 @default.
- W3201491796 creator A5038458593 @default.
- W3201491796 creator A5048156654 @default.
- W3201491796 creator A5082011377 @default.
- W3201491796 date "2021-09-15" @default.
- W3201491796 modified "2023-09-24" @default.
- W3201491796 title "Improving Biologics’ Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures" @default.
- W3201491796 cites W1495576644 @default.
- W3201491796 cites W1518184777 @default.
- W3201491796 cites W1541202145 @default.
- W3201491796 cites W1561050353 @default.
- W3201491796 cites W1735373984 @default.
- W3201491796 cites W1967690555 @default.
- W3201491796 cites W1968961303 @default.
- W3201491796 cites W1969175190 @default.
- W3201491796 cites W1984778395 @default.
- W3201491796 cites W1987270095 @default.
- W3201491796 cites W1992815045 @default.
- W3201491796 cites W2002226820 @default.
- W3201491796 cites W2029806600 @default.
- W3201491796 cites W2034963044 @default.
- W3201491796 cites W2037276343 @default.
- W3201491796 cites W2045877726 @default.
- W3201491796 cites W2054445609 @default.
- W3201491796 cites W2066471812 @default.
- W3201491796 cites W2069496741 @default.
- W3201491796 cites W2084501883 @default.
- W3201491796 cites W2092835606 @default.
- W3201491796 cites W2105330984 @default.
- W3201491796 cites W2107335150 @default.
- W3201491796 cites W2112510510 @default.
- W3201491796 cites W2112601576 @default.
- W3201491796 cites W2113404235 @default.
- W3201491796 cites W2116407319 @default.
- W3201491796 cites W2118486765 @default.
- W3201491796 cites W2119479524 @default.
- W3201491796 cites W2123591186 @default.
- W3201491796 cites W2127640925 @default.
- W3201491796 cites W2131730234 @default.
- W3201491796 cites W2133520325 @default.
- W3201491796 cites W2137950260 @default.
- W3201491796 cites W2140046604 @default.
- W3201491796 cites W2143163879 @default.
- W3201491796 cites W2143902539 @default.
- W3201491796 cites W2147142361 @default.
- W3201491796 cites W2153636914 @default.
- W3201491796 cites W2162827805 @default.
- W3201491796 cites W2165279742 @default.
- W3201491796 cites W2166199281 @default.
- W3201491796 cites W2166662937 @default.
- W3201491796 cites W2168236082 @default.
- W3201491796 cites W2169738708 @default.
- W3201491796 cites W2176000775 @default.
- W3201491796 cites W2177888539 @default.
- W3201491796 cites W2205886515 @default.
- W3201491796 cites W2265437850 @default.
- W3201491796 cites W2321034019 @default.
- W3201491796 cites W2464310892 @default.
- W3201491796 cites W2468644245 @default.
- W3201491796 cites W2489570902 @default.
- W3201491796 cites W2567281524 @default.
- W3201491796 cites W2605792367 @default.
- W3201491796 cites W2607282543 @default.
- W3201491796 cites W2621366507 @default.
- W3201491796 cites W2624590002 @default.
- W3201491796 cites W2727633585 @default.
- W3201491796 cites W2729889468 @default.
- W3201491796 cites W2738953894 @default.
- W3201491796 cites W2741061204 @default.
- W3201491796 cites W2743088462 @default.
- W3201491796 cites W2753432434 @default.
- W3201491796 cites W2773830451 @default.
- W3201491796 cites W2777976425 @default.
- W3201491796 cites W2784868445 @default.
- W3201491796 cites W2786457978 @default.
- W3201491796 cites W2791610452 @default.
- W3201491796 cites W2799579330 @default.
- W3201491796 cites W2799596353 @default.
- W3201491796 cites W2801657532 @default.
- W3201491796 cites W2804661897 @default.
- W3201491796 cites W2805250652 @default.
- W3201491796 cites W2805354595 @default.
- W3201491796 cites W2809980410 @default.
- W3201491796 cites W2885136634 @default.
- W3201491796 cites W2885504314 @default.
- W3201491796 cites W2892163061 @default.
- W3201491796 cites W2896600825 @default.
- W3201491796 cites W2904585369 @default.
- W3201491796 cites W2907759226 @default.
- W3201491796 cites W2914160668 @default.
- W3201491796 cites W2914643394 @default.
- W3201491796 cites W2957607325 @default.
- W3201491796 cites W2971275989 @default.
- W3201491796 cites W2988239315 @default.
- W3201491796 cites W3006145067 @default.
- W3201491796 cites W3025866295 @default.